 RICHMOND, Va.--BUSINESS WIRE--Aditxt, Inc. Nasdaq: ADTX, a biotech innovation company with a mission to improve the health of the immune system, today announced that it has signed a letter of intent the LOI to acquire a biopharmaceutical company, the Target Company, commercializing COVID-19 antiviral oral therapy. The Target Company is currently selling its products under emergency and compassionate use, standard of care, and full approval in multiple countries internationally outside 